PhD | Director Therapeutic Innovation and BaseLaunch
Tel. +41 61 295 50 17stephan. emmerth@baselarea. swiss
The pharmaceutical research company Idorsia has enjoyed a successful launch following its demerger from Actelion. Its first drug candidates have already welcomed positive results.
Idorsia was founded by a demerger following Actelion’s acquisition by Johnson & Johnson and started operational business on 15th June. The company has now published its first half-year results, which refer to the period from the middle to the end of June.
"We launched Idorsia on 15 June 2017 with a fully operational research and development engine and CHF 1 billion in cash. For the shortened financial year of 2017, we expect our non-GAAP operating expenses to be between CHF 180-190 million," said chief financial officer, Andre C. Müller, of the results.
In the research field, Idorsia achieved positive results for two drug candidates. The company conducted a phase 2 dose-finding results trial with aprocitentan, which was developed to treat resistant hypertension and will now move into phase 3 development.
The dual orexin receptor antagonist (DORA) ACT-541468 also achieved positive results in a phase 2 trial in insomnia. This drug will also now enter a phase 3 trial.
"I am very pleased and proud that we are fully functional after the successful demerger from Actelion. Innovation is and will always be the key to our success,” commented CEO Jean-Paul Clozel.